Dual Antiplatelet Therapy Improves Outcomes After Stent Implantation

The A‑CLOSE trial, presented in a Hot Line session at the 2026 European Society of Cardiology Congress, found that antiplatelet monotherapy after stent implantation reduces bleeding risk, while dual antiplatelet therapy offers superior protection against cardiovascular events in high‑ischemic‑risk patients who had a stent placed 12 months earlier. The study’s results were released concurrently with a publication in the *New England Journal of Medicine*.

In the randomized trial, patients who had undergone percutaneous coronary intervention with stent placement one year prior were assigned to either a single antiplatelet agent or a combination of two agents. The monotherapy group experienced a statistically significant lower incidence of major bleeding events compared with the dual‑therapy group. Conversely, the dual‑therapy cohort showed a notable reduction in major adverse cardiovascular events, including myocardial infarction and stroke, underscoring the trade‑off between bleeding risk and ischemic protection.

These findings provide clinicians with evidence to tailor antiplatelet strategies based on individual ischemic and bleeding risk profiles, particularly in patients with a history of stent implantation. The simultaneous release of the data in a high‑profile conference session and a peer‑reviewed journal highlights the clinical relevance and urgency of incorporating these results into practice guidelines.